These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7907184)

  • 21. Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.
    Elizur A; Segal S; Yeret A; Ben-David M
    Isr Ann Psychiatr Relat Discip; 1979 Dec; 17(4):318-27. PubMed ID: 44877
    [No Abstract]   [Full Text] [Related]  

  • 22. Zotepine, a neuroleptic drug with a bipolar therapeutic profile.
    Dieterle DM; Ackenheil M; Müller-Spahn F; Kapfhammer HP
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):52-7. PubMed ID: 2883683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ionized calcium and neuroleptic-induced extrapyramidal symptoms.
    Kuny S; Binswanger U
    Pharmacopsychiatry; 1988 Nov; 21(6):300-1. PubMed ID: 2907631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
    Gerken A; Wetzel H; Benkert O
    Pharmacopsychiatry; 1991 Jul; 24(4):132-7. PubMed ID: 1754609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrapyramidal side effects: a historical perspective.
    Rifkin A
    J Clin Psychiatry; 1987 Sep; 48 Suppl():3-6. PubMed ID: 2887555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The concept of the neuroleptic threshold: an update.
    Bitter I; Volavka J; Scheurer J
    J Clin Psychopharmacol; 1991 Feb; 11(1):28-33. PubMed ID: 1674947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria.
    Gerlach J
    Ann Clin Psychiatry; 2002 Mar; 14(1):47-57. PubMed ID: 12046640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiles of clinical efficacy and pharmacological action of zotepine.
    Yamawaki S
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):4-7. PubMed ID: 2883681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neuroleptic induced deficit syndrome].
    Szafrański T
    Psychiatr Pol; 1995; 29(3):359-69. PubMed ID: 7652089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of high-dosage neuroleptic therapy and electroshock in the treatment of the acute phase of schizophrenia].
    Ungvári G; Bitter I; Czobor P; Vitrai J; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Aug; 33(8):458-63. PubMed ID: 6124987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between neuroleptic dose and positive and negative symptoms.
    Johnson PB; Ramirez PM; Opler LA; Malgady R
    Psychol Rep; 1994 Apr; 74(2):481-2. PubMed ID: 7910976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia.
    Jody D; Lieberman JA; Geisler S; Szymanski S; Alvir JM
    Psychopharmacol Bull; 1990; 26(2):224-30. PubMed ID: 2236460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764).
    Floru L; Tegeler J
    Arzneimittelforschung; 1978; 28(2):341-4. PubMed ID: 25071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic-induced extrapyramidal symptoms and serum calcium levels. Results of a pilot study.
    Kuny S; Binswanger U
    Neuropsychobiology; 1989; 21(2):67-70. PubMed ID: 2575718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with the neuroleptic zotepine--first results.
    Haug HJ
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):35-7. PubMed ID: 2883679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychological factors in susceptibility to drug-induced extrapyramidal symptoms.
    Levinson P; Malen R; Hogben G; Smith H
    Am J Psychiatry; 1978 Nov; 135(11):1375-6. PubMed ID: 707640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Usefulness for differential diagnosis of the distribution of extrapyramidal symptoms resulting from neuroleptic therapy in psychiatric practice].
    Bódog G
    Psychiatr Neurol Med Psychol (Leipz); 1976 Jan; 28(1):51-7. PubMed ID: 940883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
    Greenberg JS; Brown WA; Laughren TP; Krantz J
    Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
    [No Abstract]   [Full Text] [Related]  

  • 40. [Predictors of the course of schizophrenic diseases under neuroleptic long-term medication (author's transl)].
    Gaebel W; Pietzcker A; Poppenberg A
    Pharmacopsychiatria; 1981 Sep; 14(5):180-8. PubMed ID: 6117091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.